跳至主要内容
临床试验/NL-OMON43020
NL-OMON43020已完成不适用

Activation of the innate immune system in patients with primary hyperaldosteronism - Innate immune activation in hyperaldosteronism

Radboud Universitair Medisch Centrum0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • Patients with PA (primary hyperaldosteronism):
  • - Diagnosis of PA according to current guideline
  • - Age >=18 yrs
  • - Written informed consent;Patients with essential hypertension:
  • - Exclusion of PA according to current guidelines
  • - Age >=18 yrs
  • - Written informed consent

排除标准

  • - Treatment with MR antagonists within the 4 weeks before participation
  • - Diabetes mellitus
  • - Previous cardiovascular events (stroke, TIA, myocardial infarction)
  • - Heart failure
  • - Auto-inflammatory or auto-immune diseases
  • - Use of immunomodulating drugs
  • - Renal failure (MDRD <45)
  • - BMI >35
  • - Previous vaccination within 3 months prior to study entry.
  • - Current infection or clinically significant infections within 3 months before participation (defined as fever >38.5).

研究者

相似试验